The UK and US have concluded a important commercial pact that will keep zero import taxes on British pharmaceutical products going into the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on drugs through the NHS. This move guarantees that duties on these key goods will remain at nothing for a duration of 36 months.
This deal follows recent warnings to hike duties on patented drug products, with figures floated up to one hundred percent.
"This deal with the UK bolsters the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. medicine commerce," a statement noted.
Economic Significance
Pharmaceuticals are one of the UK's most significant export categories to the United States, which is by far the biggest destination for leading companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to September, the UK shipped medicines valued at £11.1bn to the US. This figure represented 17.4% of total UK exports in that span.
"This deal secures employment, boosts funding and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The pact entails several key commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be restricted at 15%. Last year, refunds were more than 20%.
Broader Context
The deal comes amid a long-running dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were heightened by arguments that American consumers were paying significantly more for the same drugs than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been paused or cancelled, while major expansions have been pledged toward American operations.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the past decade.
